Accounts Payable

3 Months Ended

Mar. 31, 2019

Accounts Payable Disclosure [Abstract]

Accounts Payable

5. Accounts Payable

As of March 31, 2019, Current Liabilities included accounts payable of $0.6 million, comprised primarily of amounts owed to the Company’s clinical research organizations for our clinical trials for prexigebersen in AML and CML of $0.3 million, legal expenses of $0.2 million and other payables of $0.1 million. As of December 31, 2018, Current Liabilities included accounts payable of $0.8 million, comprised primarily of amounts owed to the Company’s clinical research organizations for our clinical trials for prexigebersen in AML and CML of $0.3 million, preclinical expenses of $0.2 million, an annual license maintenance fee of $0.1 million, manufacturing costs of $0.1 million and other payables of $0.1 million.